| Home | E-Submission | Sitemap | Contact Us |  
top_img
J Korean Soc Ther Radiol Oncol > Volume 24(3); 2006 > Article
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2006;24(3): 171-178.
Preliminary Results of Concurrent Chemotherapy and Radiation Therapy using High-dose-rate Brachytherapy for Cervical Cancer
Kyung Ja Lee, Jihye Lee, Rena Lee, Hyunsuk Suh
Department of Radiation Oncology, Mokdong Hospital, Ewha Womans University, College of Medicine, Seoul, Korea. rokjlee@ewha.ac.kr
ABSTRACT
PURPOSE:
To determine the efficacy and safety of concurrent chemotherapy and radiation therapy with high-dose-rate brachytherapy for cervical cancer.
MATERIALS AND METHODS:
From January 2001 to December 2002, 30 patients with cervical cancer were treated with concurrent chemotherapy (cisplatin and 5-FU) and definitive radiation therapy. The median age was 58 (range 34~74) year old. The pathology of the biopsy sections was squamous cell carcinoma in 29 patients and one was adenocarcinoma. The distribution to FIGO staging system was as follows: stage IB, 7 (23%); IIA, 3 (10%); IIB, 12 (40%); IIIA, 3 (10%); IIIB, 5 (17%). All patients received pelvic external beam irradiation (EBRT) to a total dose of 45~50.4 Gy (median: 50.4 Gy) over 5~5.5 weeks. Ir-192 HDR intracavitary brachytherapy (ICBT) was given after a total dose of 41.4 Gy. HDR-ICBT was performed twice a week, with a fraction point A dose of 4 Gy and median dose to point A was 28 Gy (range: 16~32 Gy) in 7 fractions. The median cumulative biologic effective dose (BED) at point A (EBRT+ICBT) was 88 Gy10 (range: 77~94 Gy10). The median cumulative BED at ICRU 38 reference point (EBRT+ICBT) was 131 Gy3 (range: 122~140 Gy3) at point A, 109 Gy3 (range: 88~125 Gy3) at the rectum and 111 Gy3 (range: 91~123 Gy3) at the urinary bladder. Cisplatin (60 mg/m2) and 5-FU (1,000 mg/m2) was administered intravenously at 3 weeks interval from the first day of radiation for median 5 (range: 2~6) cycles. The assessment was performed at 1 month after completion of radiation therapy by clinical examination and CT scan. The median follow-up time was 36 months (range: 8~50 months).
RESULTS:
The complete response rate after concurrent chemoradiation therapy was 93.3%. The 3-yr actuarial pelvic control rate was 87% and 3-yr actuarial overall survival and disease-free survival rate was 93% and 87%, respectively. The local failure rate was 13% and distant metastatic rate was 3.3%. The crude rate of minor hematologic complications (RTOG grade 1-2) occurred in 3 patients (10%) and one patient had suffered from severe leukopenia (RTOG grade 4) during concurrent treatment. Acute minor enterocolitis (RTOG grade 1-2) occurred in 11 patients (37%) and one patient (3%) was suffered from colon perforation during radiation therapy. Late colitis of RTOG grade 1 occurred in 5 patients (15%). Acute cystitis of RTOG grade 1 occurred in 12 patients (40%) and late cystitis of RTOG grade 2 occurred in one patient (3%). No treatment related death was seen.
CONCLUSION:
The results of this study suggest that the concurrent chemoradiation therapy with HDR brachytherapy could be accepted as an effective and safe treatment for cervical cancer.
Key Words: Cervical cancer, Chemoradiation therapy, HDR brachytherapy
Editorial Office
Department of Radiation Oncology,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
81 Irwon-Ro, Gangnam-gu, Seoul 06351, Korea
TEL: +82-2-3410-2612  E-mail: rojeditor@gmail.com
Copyright © The Korean Society for Radiation Oncology. All rights reserved.                      developed in m2community
Close layer
prev next